Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor Dosing Invited Commentary Invited Commentary The SCORE2 Comparison of Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor Dosing Short-term Similarities and Longer-term Questions Jennifer K. Sun, MD, MPH Therapy with anti–vascular endothelial growth factor (anti- cept and bevacizumab groups received statistically signifi- VEGF) agents has dramatically improved visual outcomes for cantly fewer injections on average (2 and 1.3 fewer injections, respectively), the clinical relevance of this point estimate of a patients with various retinal vascular diseases, including reti- nal vascular occlusion, diabetic macular edema, and neovas- 0.7-injection difference between groups over 6 months is un- cular age-related macular de- known. As might be expected in this short-duration, mod- generation. Landmark phase estly sized study, there were no differences in the safety pro- Related article 3 randomized clinical trials file that were identified between the treatment groups. These comparing anti-VEGF alter- results may be helpful to clinicians who are trying to choose natives have answered key questions regarding their compara- between treatment strategies by providing evidence that a TAE 1-3 tive effectiveness in these diseases. However, a remaining treatment strategy reduces the numbers of burdensome in- issue that faces physicians is how to choose
JAMA Ophthalmology – American Medical Association
Published: Apr 24, 2018
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud